NCT06207864 Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
| NCT ID | NCT06207864 |
| Status | Recruiting |
| Phase | — |
| Sponsor | New Mexico Cancer Research Alliance |
| Condition | Malignant Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,001 participants |
| Start Date | 2022-03-22 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,001 participants in total. It began in 2022-03-22 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies engagement strategies for recruiting American Indians (AI) of Southwestern Tribal Nations for cancer genome sequencing. American Indians in the Southwest have higher rates of some types of cancer, such as cancers that arise in the liver, kidney, breast, and colon. American Indians with cancer may also live for less time than people from other population groups who have been treated for the same cancer. Damage to the cells of the body, acquired as people live, grow older, and are exposed to the environment, causes genetic changes in cells that can lead to cancer. This study may help researchers learn how these genetic changes in cells cause cancer and understand how and why cancer is arising in American Indians in the Southwest. This may help better prevent and treat cancer in the future.
Eligibility Criteria
Inclusion Criteria: * The PE-CGS Research Center is only recruiting and sequencing tumors for adult-onset cancers (patients and survivors) among the American Indian Tribes, Nations, and Pueblos of New Mexico and adjacent states * Male or female adults (18 years) or older * Cancer patient undergoing active treatment or a cancer survivor * Self-identify as American Indian Exclusion Criteria: * Cognitively impaired * Adults unable to consent for themselves * Individuals who are not yet adults * Prisoners
Contact & Investigator
Cheryl Willman, MD
PRINCIPAL INVESTIGATOR
University of New Mexico Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06207864 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06207864 currently recruiting?
Yes, NCT06207864 is actively recruiting participants. Contact the research team at ASussman@salud.unm.edu for enrollment information.
Where is the NCT06207864 trial being conducted?
This trial is being conducted at Albuquerque, United States.
Who is sponsoring the NCT06207864 clinical trial?
NCT06207864 is sponsored by New Mexico Cancer Research Alliance. The principal investigator is Cheryl Willman, MD at University of New Mexico Comprehensive Cancer Center. The trial plans to enroll 1,001 participants.